ArticleCancer immunology, immunotherapy : CII2005
Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy.
Article in Cancer immunology, immunotherapy : CII, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 71 citations in OpenAlex.
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.Nature medicine · 2012Trial
- Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review.Bioengineering (Basel, Switzerland) · 2023Review
- Immune classification of clear cell renal cell carcinoma.Scientific reports · 2021Article
- RGS5 plays a significant role in renal cell carcinoma.Royal Society open science · 2020Article
- Cross-sectional analysis of CD8 T cell immunity to human herpesvirus 6B.PLoS pathogens · 2018Article
- Landscape of Tumor Antigens in T Cell Immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2015Review
- T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.Journal of virology · 2015Article
- Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer.Cancer immunology, immunotherapy : CII · 2013Article
- Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.Blood · 2012Review
- A CD74-dependent MHC class I endolysosomal cross-presentation pathway.Nature immunology · 2012Article
- Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.Proteomics · 2011Article
- MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.PloS one · 2011Article
- Identification of potential HLA class I and class II epitope precursors associated with heat shock protein 70 (HSPA).Cell stress & chaperones · 2010Article
- Placental leucine aminopeptidase efficiently generates mature antigenic peptides in vitro but in patterns distinct from endoplasmic reticulum aminopeptidase 1.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells.Cancer immunology, immunotherapy : CII · 2010Article
- Article
- HLA ligand profiles of primary renal cell carcinoma maintained in metastases.Cancer immunology, immunotherapy : CII · 2009Article
- Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells.Cancer immunology, immunotherapy : CII · 2008Article
- C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma.Cancer science · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of sufficient well-defined tumor-associated antigens is still a drawback on the way to a cytotoxic T-lymphocyte-based immunotherapy of renal cell carcinoma (RCC). We are trying to define a larger number of such targets by a combined approach involving HLA ligand characterization by mass spectrometry and gene expression profiling by oligonucleotide microarrays. Here, we present the results of a large-scale analysis of 13 RCC specimens. We were able to identify more than 700 peptides, mostly from self-proteins without any evident tumor association. However, some HLA ligands derived from previously known tumor antigens in RCC. In addition, gene expression profiling of tumors and a set of healthy tissues revealed novel candidate RCC-associated antigens. For several of them, we were able to characterize HLA ligands after extraction from the tumor tissue. Apart from universal RCC antigens, some proteins seem to be appropriate candidates in individual patients only. This underlines the advantage of a personalized therapeutic approach. Further analyses will contribute additional HLA ligands to this repertoire of universal as well as patient-individual tumor antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.